Aurinia Pharmaceuticals Sees Unusually High Options Volume (AUPH)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) saw some unusual options trading on Wednesday. Stock traders bought 1,453 put options on the company. This represents an increase of approximately 1,946% compared to the typical volume of 71 put options.

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.57 on Friday. Aurinia Pharmaceuticals has a fifty-two week low of $2.38 and a fifty-two week high of $10.54. The company has a market capitalization of $461.01, a price-to-earnings ratio of -4.60 and a beta of 2.34.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. The business’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts predict that Aurinia Pharmaceuticals will post -1.08 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of AUPH. Royal Bank of Canada lifted its position in shares of Aurinia Pharmaceuticals by 8.6% in the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after buying an additional 1,341 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Aurinia Pharmaceuticals by 13,197.5% in the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after buying an additional 26,395 shares in the last quarter. Investment Centers of America Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the second quarter worth about $184,000. Cutler Capital Management LLC lifted its position in shares of Aurinia Pharmaceuticals by 33.3% in the third quarter. Cutler Capital Management LLC now owns 40,000 shares of the biotechnology company’s stock worth $251,000 after buying an additional 10,000 shares in the last quarter. Finally, Kazazian Asset Management LLC lifted its position in shares of Aurinia Pharmaceuticals by 47.3% in the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock worth $406,000 after buying an additional 21,304 shares in the last quarter. Institutional investors own 28.13% of the company’s stock.

A number of research analysts have recently commented on AUPH shares. Zacks Investment Research cut Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. HC Wainwright restated a “buy” rating and issued a $12.00 target price (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a research note on Monday, October 30th. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. Leerink Swann raised their target price on Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Finally, Seaport Global Securities restated a “buy” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $10.79.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/20/aurinia-pharmaceuticals-sees-unusually-high-options-volume-auph.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Aurinia Pharmaceuticals Sees Unusually High Options Volume (AUPH)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was the target of unusually large options trading activity on Wednesday. Stock traders acquired 3,526 call options on the company. This is an increase of 1,595% compared to the typical daily volume of 208 call options.

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Aurinia Pharmaceuticals by 0.3% during the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock valued at $35,969,000 after buying an additional 19,200 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Aurinia Pharmaceuticals by 357.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after buying an additional 684,816 shares during the period. Alyeska Investment Group L.P. raised its position in shares of Aurinia Pharmaceuticals by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after buying an additional 12,171 shares during the period. Balyasny Asset Management LLC raised its position in Aurinia Pharmaceuticals by 66.7% in the second quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $3,065,000 after purchasing an additional 200,000 shares during the period. Finally, AWM Investment Company Inc. raised its position in Aurinia Pharmaceuticals by 17.5% in the second quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 52,500 shares during the period. 28.13% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) opened at $5.57 on Friday. The company has a market cap of $461.01, a P/E ratio of -4.60 and a beta of 2.34. Aurinia Pharmaceuticals has a 12-month low of $2.38 and a 12-month high of $10.54.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The firm’s revenue was up .0% on a year-over-year basis. analysts predict that Aurinia Pharmaceuticals will post -1.08 earnings per share for the current year.

A number of research firms have weighed in on AUPH. Seaport Global Securities reissued a “buy” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, October 6th. Leerink Swann raised their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. Canaccord Genuity set a $11.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 24th. Finally, Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Aurinia Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $10.79.

COPYRIGHT VIOLATION WARNING: “Aurinia Pharmaceuticals Sees Unusually High Options Volume (AUPH)” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/20/aurinia-pharmaceuticals-sees-unusually-high-options-volume-auph.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply